CClinicalTrials.gg
RecruitingNCT06697288Updated Nov 20, 2024

Evaluation of Efficacy of Anthelios Sunscreen on Face Versus Usual Routine on Signs of Aging

An interventional study of Tested product group and Control group in Aging, sponsored by Cosmetique Active International. Recruiting at 1 site in Brazil. Open to participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-20.

Sponsored by Cosmetique Active International · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Registered 7 months after the study started (first participant enrolled Apr 2024, registered Nov 2024).
  • Started Apr 2024; still recruiting 2 years 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
30 Years to 60 Years
Sex
All
01

Study summary

This experimental, randomized study aims at evaluating the preventative effect of a Sun Protection Factor (SPF) 50+ sunscreen (Anthelios UVMUNE 400 Fluid SPF 50+) with high Ultraviolet A (UVA) protection on clinical signs of skin aging.

Read the detailed description

The study will be conducted in compliance with the protocol, current internal procedures and in the spirit of the International Council on Harmonisation (ICH) Topic E6(R2)5 ref: EMA/CHMP/ICH/135/1995, ICH Good Clinical Practice (GCP) Addendum Nov 2016 and applicable regulatory requirement.

Statistical plan: Tx represents the values observed at Time x, for each parameter and by subgroup. Quantitative variables, or those that can reasonably be treated as such, will be summarized using the minimum, maximum, measures of central tendency such as the mean and median \& measures of dispersion such as the standard deviation (SD). Qualitative variables will be summarized in the form of counts and percentages.

For each parameter, a graphical representation of the means ±95% Confidence Interval (CI) will be produced to visually assess the evolution across time, by treatment group.

02

Conditions studied

  • Aging

Keywords

  • skin aging
  • Anthelios UVMUNE 400 Oil Control Fluid SPF 50+
  • preventive effect
03

In context

Lead sponsor

Cosmetique Active International is the lead sponsor of 54 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Subjects with signs of photo aging (Global score of at least 14)
  • All skin types

Exclusion criteria

Exclusion Criteria:

  • Any history of significant dermatological/ophthalmological diseases or conditions or medical conditions known to alter skin appearance or physiologic response (e.g. diabetes,) which could, in the opinion of the Investigator, preclude topical application of the investigational products and/or interfere with the evaluation of the test site
  • Pregnant or breastfeeding women
  • Subject with known allergy to cosmetic products or to any ingredient of the sunscreen product
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Tested product group

    Volunteers using the investigational product handed over to them

    Other: Tested product group

  • Active comparator
    Control group

    Volunteers using their own sun protection routine

    Other: Control group

Interventions

  • OtherTested product group

    Apply the test product per zone at least twice a day on the face, neck (neck \& nape), décolleté and back of the hand in the morning and at midday whatever the weather conditions and the activities of the day

  • OtherControl group

    Maintain their normal routine of using cosmetics (cleansers and moisturizers) and normal sun protection habits (if applicable)

06

What researchers measure

Primary outcomes

  1. Change in the dermatological assessment of skin signs on the face (Global score)

    Assessment of the skin parameters: Skin roughness \[absent (0), mild (2), moderate (4), severe (6)\]; Skin laxity \[absent (0), mild (2), moderate (4), severe (6)\]; Skin suppleness \[high(0), moderate (2),low (4), absent (6)\]; Skin radiance \[highly radiant (0), radiant (2), normal(4), dull(6), highly dull(8)\]; Pigmented spots \[absent (0), visible (2), highly visible (4)\]; Skin tone homogeneity \[homogeneous (0), non-homogeneous (2)\].

    Time frame: Day0; Day84; Day168; Day252; Day336

Secondary outcomes

  1. Dermatological assessment of skin signs on the face - Atlas Bazin, Flament (Global score)

    Assessment of the skin parameters: Forehead wrinkles (0 - 5); Crow feet wrinkles number (1 - 4); Crow feet wrinkles deepness (1 - 6); Glabellar wrinkles (0 - 5); Glabellar fine lines (0 - 5); Underneath eye wrinkle (0 - 5); Corner mouth wrinkle (0 - 6); Nasolabial fold (0 - 5); Upper lip wrinkles (0 - 6); Neck fold (0 - 5); Neck sagging (0 - 5); Ptosis (0 - 5); Eye bags (0 - 5

    Time frame: Day0; Day84; Day168; Day252; Day336

07

Study locations

1 of 1 sites recruiting
  • CIDP
    Rio de Janeiro, 20231-048, Brazil
    • Renato Moura · Contact
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06697288
Lead sponsor
Cosmetique Active International
Responsible party
Sponsor
First posted
Nov 20, 2024
Start date
Apr 3, 2024
Primary completion
Aug 2025 (estimated)
Completion
Aug 2025 (estimated)
Last update
Nov 20, 2024

Study contacts

Renato Moura
Contact
renato.moura.b@gmail.com
(55) 21 2221 6180
Renato Moura
principal investigator · Centre International de Développement Pharmaceutique

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion